Travere Therapeutics (TVTX) Returned To Losses In Q3, Is A 31% Discount Warranted?

Q3 earnings spotlight for Travere Therapeutics

Travere Therapeutics (TVTX) just put fresh numbers on the table. Third quarter revenue came in at US$224.56 million while the business swung to a net loss of US$52.34 million.

Travere Therapeutics shares closed at US$51.63 after the earnings release, with a 1-day share price return of 4.09% capping a 7-day gain of 4.81%. However, the 90-day share price return is down 14.25%, even as the 1-year total shareholder return is 50.17% and the 3-year total shareholder return is very large. This points to strong long term momentum despite a softer recent patch and fresh scrutiny following the move back into losses and the upcoming Guggenheim presentation on 10 November 2026.

Seize this earnings reset in Travere Therapeutics to reassess your watchlist alongside a curated group of resilient healthcare and biotech names in the 30 resilient stocks with low risk scores.

Travere Therapeutics now trades well below both analyst targets and an estimated intrinsic value, even as the market reacts to the swing back into losses. Is that discount a sign of caution or a case of mispricing?

Most Popular Narrative: 31% Undervalued

Travere Therapeutics closed at $51.63 against a fair value estimate of $75.14 from the analyst consensus Narrative on Simply Wall St. This estimate applies a 7.72% discount rate and ties that valuation directly to detailed revenue and earnings forecasts.

The main thing that has to go right is that Travere Therapeutics turns FILSPARI's growing U.S. sales, extended patent protection into 2037, and dual indications in IgA nephropathy and FSGS into durable cash generation, while successfully advancing pegtibatinase and civorebrutinib toward future launches.

The current numbers on FILSPARI sales, the multibillion management sales target, extended intellectual property, and strong institutional ownership together imply that the share price does not fully reflect the potential value of Travere Therapeutics' rare kidney and metabolic disease franchise.

See why 23 investors see Travere Therapeutics as 31% undervalued.

Result: Fair Value of $75.14 (UNDERVALUED)

Still, the Travere Therapeutics story can change quickly if FILSPARI demand softens or if high R&D and licensing costs continue to weigh on earnings.

Find out about the key risks to this Travere Therapeutics narrative.

Next Steps

Confident about the Travere Therapeutics story so far, or still on the fence? Use the full dataset to stress test your thesis, then weigh the 4 key rewards.

Looking for more investment ideas beyond Travere Therapeutics?

Do not stop with Travere Therapeutics when there are other potential opportunities on the table. Put the same discipline to work on a broader watchlist using the Simply Wall St Screener.

• Target stronger balance sheets by reviewing companies in the list of solid balance sheet and fundamentals (25 results) that may handle shocks better than more fragile peers.
• Hunt for potential mispricing by scanning the 33 high quality undervalued stocks where quality and price meet a stricter hurdle.
• Spot early-stage potential by checking the 11 elite penny stocks with strong financials that pair smaller size with more robust financial profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com